Seaside Therapeutics, a developer of drug treatments to correct or improve the course of Fragile X Syndrome, autism and other disorders of brain development, secured $30 million in financing from an undisclosed private investment firm.
The financing, which brings the total capital raised by the Cambridge, MA.-based company to $66m, will be used to fund the Seaside’s pipeline of novel therapeutic candidates to correct or improve the course of those who suffer these disorders.
As explained by Randall L. Carpenter, M.D., President and Chief Executive Officer of Seaside, this financial commitment will support the Phase 2 studies of its first clinical candidate STX209 in both autism and Fragile X and the initiation of a second clinical candidate, STX107, into Phase 1 studies in Fragile X in early October.
FinSMEs
17/09/2009